Bile Acids: Major Regulator of the Gut Microbiome

An, Chihyeok; Chon, Hye Yeon; Ku, Wanrim; Eom, Sunho; Seok, Mingyu; Kim, Sang-Ha; Lee, Jaesun; Kim, Dae Sung; Lee, Sanghyuk; Koo, Hoonsup; Cho, Hyunjung; Han, Seung‐Yun; Moon, Juik; Kang, Miil; Ryu, Ki Hyun

doi:10.3390/microorganisms10091792

Cited by 14 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between PPIs and infectious diseases of the biliary system has been discussed in several clinical studies ( Chuang et al, 2019 ; Min et al, 2019 ). The biliary system typically maintains a sterile environment with bile acids ( D'Aldebert et al, 2009 ); however, a recent study proposes that there is a clear transfer of intestinal microorganisms to the biliary tract in patients with biliary tract diseases ( An et al, 2022 ). Additionally, animal models of SIBO revealed that intestinal flora and metabolites can affect bile acid metabolism and cause biliary disease ( Almeida et al, 2013 ); overall, this establishes a correlation between biliary system disease and the intestinal microbiota.…”

Section: Ppi-induced Digestive System Complicationsmentioning

confidence: 99%

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Liang

Huang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.

show abstract

Section: Ppi-induced Digestive System Complicationsmentioning

confidence: 99%

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Liang

Huang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Although different defense mechanisms have been highlighted in intestinal microorganisms (i.e., active efflux system, DNA repair, and cell envelope remodeling), it is known that BAs can directly and indirectly influence gut microbiota composition through bacteriostatic and bactericidal effects and regulation of host immunity ( 67 , 111 – 113 ).…”

Section: Bas and Obesity: Current Knowledgementioning

confidence: 99%

Role of bile acids in overweight and obese children and adolescents

et al. 2022

View full text Add to dashboard Cite

Bile acids (BAs) are amphipathic molecules synthetized in the liver. They are primarily involved in the digestion of nutrients. Apart from their role in dietary lipid absorption, BAs have progressively emerged as key regulators of systemic metabolism and inflammation. In the last decade, it became evident that BAs are particularly important for the regulation of glucose, lipid, and energy metabolism. Indeed, the interest in role of BA in metabolism homeostasis is further increased due to the global public health increase in obesity and related complications and a large number of research postulating that there is a close mutual relationship between BA and metabolic disorders. This strong relationship seems to derive from the role of BAs as signaling molecules involved in the regulation of a wide spectrum of metabolic pathways. These actions are mediated by different receptors, particularly nuclear farnesoid X receptor (FXR) and Takeda G protein coupled receptor 5 (TGR5), which are probably the major effectors of BA actions. These receptors activate transcriptional networks and signaling cascades controlling the expression and activity of genes involved in BA, lipid and carbohydrate metabolism, energy expenditure, and inflammation. The large correlation between BAs and metabolic disorders offers the possibility that modulation of BAs could be used as a therapeutic approach for the treatment of metabolic diseases, including obesity itself. The aim of this review is to describe the main physiological and metabolic actions of BA, focusing on its signaling pathways, which are important in the regulation of metabolism and might provide new BA -based treatments for metabolic diseases.

show abstract

“…In the small intestine, BAs emulsify dietary fats, fat-soluble vitamins, and other lipids. Under the influence of the anaerobic bacterial flora in the intestine, a number of primary BA transformations occur, including deconjugation and dehydroxylation, which lead to the formation of secondary BAs, i.e., DCA and LCA [ 60 , 61 , 62 , 63 , 64 ]. As a result of further changes, under the influence of both hepatic and intestinal mechanisms, substances of minor importance are formed, i.e., tertiary BAs: HDCA and UDCA.…”

Section: Bile Acidsmentioning

confidence: 99%

Bile Acids in Intrahepatic Cholestasis of Pregnancy

et al. 2022

View full text Add to dashboard Cite

Intrahepatic cholestasis of pregnancy (ICP) is the most common, reversible, and closely related to pregnancy condition characterized by elevated levels of bile acids (BAs) in blood serum and an increased risk of adverse perinatal outcomes. Due to the complex interactions between the mother and the fetus in metabolism and transplacental BAs transport, ICP is classified as a fetal-maternal disease. The disease is usually mild in pregnant women, but it can be fatal to the fetus, leading to numerous complications, including intrauterine death. The pathophysiology of the disease is based on inflammatory mechanisms caused by elevated BA levels. Although ICP cannot be completely prevented, its early diagnosis and prompt management significantly reduce the risk of fetal complications, the most serious of which is unexpected intrauterine death. It is worth emphasizing that all diagnostics and management of ICP during pregnancy are based on BA levels. Therefore, it is important to standardize the criteria for diagnosis, as well as recommendations for management depending on the level of BAs, which undoubtedly determines the impact on the fetus. The purpose of this review is to present the potential and importance of BAs in the detection and rules of medical procedure in ICP.

show abstract

Bile Acids: Major Regulator of the Gut Microbiome

Cited by 14 publications

References 36 publications

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Role of bile acids in overweight and obese children and adolescents

Bile Acids in Intrahepatic Cholestasis of Pregnancy

Contact Info

Product

Resources

About